Success Metrics

Clinical Success Rate
91.5%

Based on 43 completed trials

Completion Rate
91%(43/47)
Active Trials
4(6%)
Results Posted
21%(9 trials)
Terminated
4(6%)

Phase Distribution

Ph phase_1
3
4%
Ph phase_4
13
19%
Ph not_applicable
19
27%
Ph phase_2
16
23%
Ph early_phase_1
2
3%
Ph phase_3
7
10%

Phase Distribution

5

Early Stage

16

Mid Stage

20

Late Stage

Phase Distribution60 total trials
Early Phase 1First-in-human
2(3.3%)
Phase 1Safety & dosage
3(5.0%)
Phase 2Efficacy & side effects
16(26.7%)
Phase 3Large-scale testing
7(11.7%)
Phase 4Post-market surveillance
13(21.7%)
N/ANon-phased studies
19(31.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.7%

43 of 52 finished

Non-Completion Rate

17.3%

9 ended early

Currently Active

4

trials recruiting

Total Trials

70

all time

Status Distribution
Active(4)
Completed(43)
Terminated(9)
Other(14)

Detailed Status

Completed43
unknown13
Withdrawn5
Recruiting4
Terminated4
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
70
Active
4
Success Rate
91.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.3%)
Phase 13 (5.0%)
Phase 216 (26.7%)
Phase 37 (11.7%)
Phase 413 (21.7%)
N/A19 (31.7%)

Trials by Status

completed4361%
recruiting46%
terminated46%
unknown1319%
withdrawn57%
suspended11%

Recent Activity

Clinical Trials (70)

Showing 20 of 70 trialsScroll for more
NCT06803589Early Phase 1

Growth Hormone for the Treatment of Gastroparesis

Recruiting
NCT05681299Phase 4

Effects of GH and Lirglutide on AgRP

Recruiting
NCT05253287Phase 2

Growth Hormone in Decompensated Liver Cirrhosis

Completed
NCT03225755

Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

Completed
NCT03500913

Adipose Tissue and Serum Inflammation in GH Deficiency

Completed
NCT05187377Phase 2

A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

Completed
NCT05447208Phase 3

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

Recruiting
NCT00742157Phase 4

Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)

Terminated
NCT00673309Phase 2

Assessment of Mechanisms of Improved Wound Healing

Completed
NCT03420144Phase 2

Growth Hormone Therapy in Liver Cirrhosis

Completed
NCT05574894Phase 3

Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study

Completed
NCT04121780Phase 2

Growth Hormone Replacement Therapy for Retried Professional Football Players

Recruiting
NCT05660356Early Phase 1

Growth Hormone Deficiency in Mild Traumatic Brain Injury

Unknown
NCT02217345Phase 2

Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease

Completed
NCT05585177Not Applicable

Growth Hormone to Improve the Clinical Outcome of Assisted Fertility in Young Patients With Decreased Ovarian Reserve

Unknown
NCT05281341Phase 4

Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)

Completed
NCT03966339Not Applicable

Growth Hormone Adding to Controlled Ovarian Hyperstimulation for Improving Embryo Quality

Unknown
NCT02195947Phase 4

Antagonist Protocol in Poor Responders

Completed
NCT05089344Not Applicable

Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial

Unknown
NCT03616509Phase 4

GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition

Completed

Drug Details

Intervention Type
DRUG
Total Trials
70